No Data
No Data
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals
Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne
Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
loading...
No Data